Literature DB >> 4052093

Uptake of trimethoprim by renal cortex.

W Cacini, S A Myre.   

Abstract

The purpose of this study was to examine the mechanisms involved in the uptake of the urinary antibacterial drug trimethoprim by incubated slices of rat renal cortex. Concentration-dependent studies of the uptake process demonstrated that a saturable component was involved. The results of inhibitor studies as well as the time-course pattern support the conclusion that at least two processes are involved in the uptake of trimethoprim. These include active transport via the organic cation system, accounting for about 40% of the total uptake, and a second component that continues to operate under conditions of inhibited cellular metabolism. Chromatographic examination of post-incubation bathing medium and slice extracts failed to demonstrate renal cortex metabolism of trimethoprim.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052093     DOI: 10.1016/0006-2952(85)90721-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Authors:  Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

3.  Pharmacokinetic interaction between zidovudine and trimethoprim/sulphamethoxazole in HIV-1 infected children.

Authors:  S Dallas; S E Read; S King; G Koren; R Bendayan
Journal:  Can J Infect Dis       Date:  2000-09

4.  Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide.

Authors:  J Y Chatton; A Munafo; J P Chave; F Steinhäuslin; F Roch-Ramel; M P Glauser; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.